대한신장학회

Skip Navigation: Skip to contents

KOR
ENG
전체메뉴보기

간행물 검색

현재 페이지 경로

HOME
간행물
간행물 검색

논문분류	춘계학술대회 초록집
제목	Cardioprotective effect of SGLT2 inhibitor in diabetic kidney transplant recipients
저자	Oh Youn sik
출판정보	2024; 2024(1):
키워드
초록	Objectives: Kidney transplantation improves the cardiovascular outcomes of patients with end-stage kidney disease. However, cardiovascular disease remains the leading cause of premature death and graft loss in kidney transplant recipients (KTRs) with diabetes. We evaluated the cardioprotective effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in KTRs with diabetes. Methods: A total of 750 KTRs with diabetes were enrolled from six tertiary hospitals. Among them, 129 (17.2%) patients were prescribed SGLT2i. The primary outcome was the incidence of major adverse cardiovascular events (MACE), which comprised of myocardial infarction (MI), death from cardiovascular causes, hospitalization for heart failure, and stroke. Multivariable Cox regression analysis and propensity score matching were used to investigate the effect of SGLT2i on clinical outcomes. Results: During a mean of 55.7 months, MACE occurred in 6 out of 129 (4.7%) and 78 out of 621 (12.6%) patients in the SGLT2i and non-SGLT2i groups, respectively. The incidence of MACE, MI, and death from cardiovascular causes was lower in the SGLT2i group than in the non-SGLT2i group (P<0.05). Multivariable analysis revealed that the SGLT2i group had a lower risk of MACE and MI than the non-SGLT2i group(adjusted hazard ratio, 0.40 and 0.18; 95% confidence interval, 0.17–0.92 and 0.04–0.73; P=0.031 and 0.016, respectively). The propensity score-matched analysis confirmed the decreased risks of MACE and MI in the SGLT2i group. Conclusions: SGLT2i significantly decreased the risk of cardiovascular events in KTRs with diabetes, particularly lowering the incidence of MI and death from cardiovascular causes. Therefore, SGLT2i can be used to reduce the burden of cardiovascular disease in KTRs with diabetes.
원문(PDF)	PDF 원문보기

목록

위로가기